GSK And Novartis Look To Emerging Markets Even As Growth Slowed In Q1 – Emerging Market Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
You may also be interested in...
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.
The Swiss drug maker says it has agreed with FDA on a Phase III trial design for the combination respiratory drug QVA149 and expects to file in late 2014; plan now calls for testing a twice-daily dose in addition to once-daily.
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.